AAS
AMPH icon

Ameritas Advisory Services’s Amphastar Pharmaceuticals AMPH Stock Holding History

Ameritas Advisory Services’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,186
Closed -$246K – 1080
2025
Q4 		$246K Buy
+9,186
New +$237K 0.01% 835

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Ameritas Advisory Services's AMPH Position: Q1 2026 in Review

Ameritas Advisory Services sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 9,186 shares — an estimated $246K sold.

Ameritas Advisory Services first reported a position in AMPH in Q4 2025 and held it in 1 quarter. The position peaked at $246K in Q4 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Ameritas Advisory Services reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 9,186 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $246K.
  • Ameritas Advisory Services first reported a position in Amphastar Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Ameritas Advisory Services's Amphastar Pharmaceuticals position peaked at $246K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Ameritas Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.